Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Influenza virus protecting RNA : an effective prophylactic and therapeutic antiviral

Tools
- Tools
+ Tools

Dimmock, N. J., Rainsford, Edward W., Scott, P. D. (Paul D.) and Marriott, Anthony C. (2008) Influenza virus protecting RNA : an effective prophylactic and therapeutic antiviral. Journal of Virology, Vol.82 (No.17). pp. 8570-8578. doi:10.1128/JVI.00743-08

[img]
Preview
PDF
WRAP_Dimmmock_-08jvi_cloned_protecting_virus_v4njd.pdf - Requires a PDF viewer.

Download (192Kb)
[img]
Preview
PDF
WRAP_Dimmock_08Figures_for_JVI_acm_new_F7.pdf - Requires a PDF viewer.

Download (186Kb)
Official URL: http://dx.doi.org/10.1128/JVI.00743-08

Request Changes to record.

Abstract

Another influenza pandemic is inevitable, and new measures to combat this and seasonal
influenza are urgently needed. Here we describe a new concept in antivirals based on a
defined, naturally occurring defective influenza RNA that has the potential to protect against
any influenza A virus in any animal host. This protecting RNA (244 RNA) is incorporated
into virions which although non-infectious, deliver the RNA to those cells of the respiratory
tract that are naturally targeted by infectious influenza virus. A small intranasal dose of this
244 protecting virus (120 ng) completely protected mice against a simultaneous lethal (10
LD50) challenge with influenza A/WSN (H1N1) virus. 244 virus also protected mice against
a strong challenge dose of all other subtypes tested (H2N2, H3N2, H3N8). This prophylactic
activity was maintained in the animal for at least 1 week prior to challenge. 244 virus was 10
to 100-fold more active than previously characterised influenza A defective viruses, and the
protecting activity was confirmed to reside in the 244 RNA molecule by recovering a
protecting virus entirely from cloned cDNA. There was clear therapeutic benefit when
protecting 244 virus was administered 24-48 h after lethal challenge, an effect which has not
been previously observed with any defective virus. Protecting virus reduced, but did not
abolish, replication of challenge virus in mouse lungs during both prophylactic and
therapeutic treatments. Protecting virus is a novel antiviral which has the potential to combat
influenza infections in humans, particularly when the infecting strain is not known, or is
resistant to antiviral drugs.

Item Type: Journal Article
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Science > Life Sciences (2010- ) > Biological Sciences ( -2010)
Library of Congress Subject Headings (LCSH): Influenza -- Treatment, Influenza A virus, Antiviral agents, RNA viruses
Journal or Publication Title: Journal of Virology
Publisher: American Society for Microbiology
ISSN: 0022-538X
Official Date: September 2008
Dates:
DateEvent
September 2008Published
Volume: Vol.82
Number: No.17
Number of Pages: 9
Page Range: pp. 8570-8578
DOI: 10.1128/JVI.00743-08
Status: Peer Reviewed
Access rights to Published version: Restricted or Subscription Access
Funder: Mercia Spinner

Data sourced from Thomson Reuters' Web of Knowledge

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us